| Name | Title | Contact Details |
|---|
DENTSPLY International is a leading manufacturer and distributor of dental and other consumable healthcare products. Our broad global product platform helps dental professionals serve patients` oral health care for a lifetime, from preventive services to tooth replacement. DENTSPLY oral health products range from general dental consumables and laboratory products to products supporting the dental specialty markets of orthodontics, endodontics and implants. Our powerful worldwide dental sales force takes our solutions to market around the globe. Now more than 2,800 members strong, our sales team keeps us close to the dental professionals who rely on our product solutions to serve their patients` complete oral health needs. DENTSPLY’s global consumable healthcare product team provides innovative urological and surgical solutions designed to improve the quality of life for users, caregivers, and practitioners. With a presence in more than 120 countries, patients and practitioners virtually everywhere in the world rely on DENTSPLY to deliver dental and healthcare solutions with a strong focus on quality, innovation, and service.
Sira Technology Solutions Inc is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Montgomery General Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Montgomery General Hospital is based in Olney, MD. You can find more information on Montgomery General Hospital at www.montgomerygeneral.com
Apricus Health is designed by Arizona Physicians to improve access to quality care, while lowering costs.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.